Skip to content

H.R. 3884 · 118th Congress (2023–2025)

Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

This bill reauthorizes through FY2028 the Sickle Cell Disease Treatment Demonstration Program, which supports efforts to improve treatment and prevention of sickle cell disease and complications from that disease. (Sickle cell disease is an inherited blood disorder that can lead to pain, anemia, infections, and stroke.)

!--tinycomments|2.1|data:application/json;base64,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-->
Show official title

To amend title XI of the Public Health Service Act to reauthorize the program providing for sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment.

Expired in Senate committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to committee

This bill’s path

474 days after it was introduced

This is H.R. 3884’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced16 months

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Michael C. Burgess (R-TX-26)
Cosponsors
3 cosponsors

2 original · 1 later

  1. Rep. Earl L. "Buddy" Carter (R-GA-1)· Original · Jun 7, 2023
  2. Rep. Danny K. Davis (D-IL-7)· Original · Jun 7, 2023
  3. Rep. Barbara Lee (D-CA-12)· Later · Jul 19, 2023
Policy area
Health
Subjects
  • Blood and blood diseases
  • Health programs administration and funding
  • Health promotion and preventive care
  • Hereditary and development disorders
  • Medical research

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. ▸ 7 committee actions · Jun 7, 2023 – Aug 25, 2023
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
    3. Subcommittee markup session held

      Subcommittee Consideration and Mark-up Session Held

      Sources
    4. Forwarded by subcommittee

      Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 28 - 0.

      Sources
    5. Markup session held

      Committee Consideration and Mark-up Session Held.

      Sources
    6. Ordered reported

      Ordered to be Reported (Amended) by the Yeas and Nays: 50 - 0.

      Sources
    7. Reported by committee

      Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-166.

      Sources
  3. Passed House

    Congressional Record H5578

    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

    The House passed the bill as amended.

    Document: Engrossed in House

    Sources
  4. Latest

    Referred to committee

    Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Sources
  5. Expired

    Passed House → Referred to Senate Health, Education, Labor, and Pensions → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Jun 7, 2023 · Markup Jul 19, 2023 · Reported Aug 25, 2023H. Rept. 118-166
    1. Jul 19, 2023 · Markup

    1. H. Rept. 118-166 · Aug 25, 2023 · Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023
  2. HouseHealthReferred Jun 9, 2023 · Markup Jul 13, 2023 · Reported Jul 13, 2023
    1. Jul 13, 2023 · Markup

    2. Jun 14, 2023 · Meeting

  3. SenateHealth, Education, Labor, and PensionsReferred Sep 24, 2024

Floor record

i

Explicit consideration evidence: the measure’s bill-status citation matched a GovInfo title, headline, or first paragraph. Incidental mentions are not listed.

  1. Sep 23, 2024 · House · Considered under suspension of the rulesCongressional Record H5578–H5580

    Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Reported in House
Engrossed in House
Referred in Senate
Titles (2)
  1. Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

    Short title, Display title · Referred in Senate, Engrossed in House, Introduced in House, Reported in House

  2. To amend title XI of the Public Health Service Act to reauthorize the program providing for sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment.

    Official title · Introduced in House